<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425473</url>
  </required_header>
  <id_info>
    <org_study_id>Z191100006619067</org_study_id>
    <nct_id>NCT04425473</nct_id>
  </id_info>
  <brief_title>Esketamine and Perioperative Depressive Symptoms</brief_title>
  <official_title>Effect of Esketamine on Perioperative Depressive Symptoms in Patients Undergoing Major Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative depressive symptoms (PDS) are common in population undergoing surgery, and this&#xD;
      would be sharpened especially for complicated, high-risk major surgery. However, None of&#xD;
      treatments could resolve this clinical problem during limited perioperative period. The&#xD;
      remarkable effects of ketamine on treatment resistant depression have been verified by&#xD;
      several clinical trials and the enantiomer S-ketamine (esketamine) showed similar&#xD;
      antidepressant efficacy with better safety in recent studies. The efficacy and safety of&#xD;
      esketamine administrated intra-operatively for PDS will be verified in this study. Other&#xD;
      secondary outcomes such as anxiety, postoperative pain and psychiatric symptoms will also be&#xD;
      investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptoms remission</measure>
    <time_frame>Postoperative 3-day</time_frame>
    <description>Remission is defined as MADRS total score no more than 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Depressive Symptoms</condition>
  <condition>Esketamine</condition>
  <condition>Perioperative Complication</condition>
  <condition>Major Surgery</condition>
  <arm_group>
    <arm_group_label>Esketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.</description>
    <arm_group_label>Esketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Equivalent amount of normal saline will be administrated intravenously suturing incision.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing elective major surgery&#xD;
&#xD;
          -  Ages between 18 and 65 years old&#xD;
&#xD;
          -  Moderate to severe depressive symptoms ( the Patient Health Questionnaire-9 scores&#xD;
             equal to or more than 10 and Montgomery-Åsberg Depression Rating Scale scores equal to&#xD;
             or more than 22 )&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients combined with aphasia or other conditions leads that patients inability to&#xD;
             cooperate with the metal assessments;&#xD;
&#xD;
          -  Tumor related injury of the 9th, 10th, 11th, 12th cranial nerve or patients need&#xD;
             keeping intubation after surgery;&#xD;
&#xD;
          -  Medical history of psychotic or bipolar disorder;&#xD;
&#xD;
          -  Laboratory evidence of hormone levels disorder due to primary diseases;&#xD;
&#xD;
          -  Body Mass Index more than 30 kg/㎡;&#xD;
&#xD;
          -  Child-Pugh grade B or C;&#xD;
&#xD;
          -  Major depressive disorder with antidepressant therapy in the past 2 weeks before&#xD;
             screening;&#xD;
&#xD;
          -  History of adverse events to ketamine or esketamine;&#xD;
&#xD;
          -  Patients with repeated suicide attempts (QIDS-SR 12-item more than or equal to 3);&#xD;
&#xD;
          -  History of drug abused;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <phone>8610-59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

